Phaseline

Companies › Imviva Bio

Imviva Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CTD402 CAR T Cell Injection
CAR T cell therapy targeting unspecified T-ALL/LBL antigens
–Phase 1Acute Lymphocytic Leukemia RefractorySep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07070219CTD402 CAR T Cell InjectionPhase 1Acute Lymphocytic Leukemia RefractoryOncologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.